NYSEMKT: IGCIgc Pharma Inc Stock
$0.43-0.01 (-2.27%)
Updated Apr 25, 2024
IGC Price
$0.43
Fair Value Price
N/A
Market Cap
$27.41M
52 Week Low
$0.25
52 Week High
$0.91
P/E
-1.65x
P/B
3.03x
P/S
14.68x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.22M
Earnings
-$14.15M
Gross Margin
51.4%
Operating Margin
-1,163.24%
Profit Margin
-1,163.2%
Debt to Equity
0.24
Operating Cash Flow
-$6M
Beta
1.19
Next Earnings
Jun 20, 2024
Ex-Dividend
N/A
Next Dividend
N/A
IGC Overview
India Globalization Capital, Inc. purchases and resells physical infrastructure commodities. The company operates through two segments, Infrastructure Business, and Life Sciences. It buys and sells infrastructure commodities, such as steel, wooden doors, marble, and tiles; rents heavy construction equipment, including motor grader, transit mixers and rollers; and undertakes highway construction contracts. The company also develops cannabinoid-based products and therapies, such as Hyalolex for the treatment of patients from anxiety, agitation, dementia, depression, and sleep disorder diseases; and Serosapse for the treatment of Parkinson's disease. In addition, it offers offer extraction, distillation, tolling, and white labeling services under the Holi Hemp brand; and hemp crude extracts, hemp isolates, and hemp distillates. The company operates in the United States, India, and Hong Kong. India Globalization Capital, Inc. was founded in 2005 and is based in Potomac, Maryland.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IGC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IGC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IGC is good value based on its book value relative to its share price (3.03x), compared to the US Biotechnology industry average (5.8x)
P/B vs Industry Valuation
IGC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more IGC due diligence checks available for Premium users.
Be the first to know about important IGC news, forecast changes, insider trades & much more!
IGC News
Valuation
IGC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.65x
Industry
15.41x
Market
40.97x
IGC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.03x
Industry
5.8x
IGC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IGC's financial health
Profit margin
Revenue
$204.0k
Net Income
-$5.6M
Profit Margin
-2,739.7%
IGC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
IGC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$11.3M
Liabilities
$2.2M
Debt to equity
0.24
IGC's short-term assets ($3.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IGC's short-term assets ($3.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IGC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
IGC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.6M
Investing
-$61.0k
Financing
-$1.0k
IGC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IGC vs Biotech Stocks
Igc Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.